Relative gene expression was normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and is given as delta CT (dCT) value, with higher values representing lower expression levels. DREAM gene expression was significantly lower in OA patients with a high pain score (visual analog scale [VAS] score of greater than 40; △) compared with healthy controls (○) and with OA patients with a low pain score (VAS score of less than or equal to 40; ∇). No significant differences were observed between healthy controls and OA patients with a VAS score of less than or equal to 40. Statistics: one-way analysis of variance followed by Tukey's honest significant difference (*< 0.05). Ctrl, control; DREAM, downstream regulatory element antagonist modulator.<p><b>Copyright information:</b></p><p>Taken from "DREAM is reduced in synovial fibroblasts of patients with chronic arthritic pain: is it a suitable target for peripheral pain management?"</p><p>http://arthritis-research.com/content/10/3/R60</p><p>Arthritis Research & Therapy 2008;10(3):R60-R60.</p><p>Published online 28 May 2008</p><p>PMCID:PMC2483451.</p><p></p
